Parcion Private Wealth LLC grew its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 145.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,586 shares of the biopharmaceutical company’s stock after purchasing an additional 30,549 shares during the period. Parcion Private Wealth LLC’s holdings in Pfizer were worth $1,471,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Partners Wealth Management LLC bought a new position in shares of Pfizer during the 3rd quarter worth $396,000. Soltis Investment Advisors LLC lifted its holdings in shares of Pfizer by 276.7% during the 3rd quarter. Soltis Investment Advisors LLC now owns 101,626 shares of the biopharmaceutical company’s stock valued at $2,898,000 after purchasing an additional 74,645 shares during the last quarter. Founders Financial Securities LLC boosted its holdings in Pfizer by 15.3% in the third quarter. Founders Financial Securities LLC now owns 13,031 shares of the biopharmaceutical company’s stock worth $372,000 after acquiring an additional 1,725 shares in the last quarter. Blueprint Investment Partners LLC grew its position in Pfizer by 104.3% during the 3rd quarter. Blueprint Investment Partners LLC now owns 20,958 shares of the biopharmaceutical company’s stock worth $598,000 after purchasing an additional 10,699 shares during the last quarter. Finally, United Asset Strategies Inc. increased its position in shares of Pfizer by 762.9% in the 3rd quarter. United Asset Strategies Inc. now owns 231,199 shares of the biopharmaceutical company’s stock valued at $6,594,000 after acquiring an additional 204,406 shares during the period. Institutional investors own 68.36% of the company’s stock.
Trending Headlines about Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
- Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
- Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
- Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
- Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article
Pfizer Stock Up 1.8%
Shares of NYSE:PFE opened at $30.48 on Friday. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $30.67. The firm’s 50 day moving average price is $28.55 and its 200 day moving average price is $26.79. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock has a market cap of $173.73 billion, a price-to-earnings ratio of 40.11, a price-to-earnings-growth ratio of 2.07 and a beta of 0.32.
Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is 226.32%.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on the stock. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, October 13th. Scotiabank boosted their price objective on Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a research report on Tuesday, October 6th. BMO Capital Markets reduced their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Five investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.65.
Read Our Latest Stock Analysis on Pfizer
Pfizer Company Profile
Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.
The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.
Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.
Read More
- Five stocks we like better than Pfizer
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
